Beneficial neurological effects observed in a patient with psoriasis treated with Etanercept

American Journal of Clinical Dermatology

Volumn 11, Issue SUPPL. 1, 2010, Pages 44-45

  Bassi, Elisa ^a   De Filippi, Claudia ^a  

^a Lodi Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADULT; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CASE REPORT; COGNITION; DRUG EFFECT; FEMALE; HUMAN; MENTAL DEFICIENCY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; RELAPSE; SKIN DEFECT; SOCIAL INTERACTION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77954257813     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/bf03257173     Document Type: Article

References (5)

1. Tobinick EL, GrossH. Rapid improvementinverbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol 2008;2:27 (NOT 2: 27)
2. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008;9:2 5: 2 (NOT 9: 2)
3. Di Nuzzo S, Zanni M, De Panfilis G. Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporin A, but not with etanercept. J Drugs Dermatol 2007;6:1046-7
4. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007;157:1275-7
5. Evers AWM, Lu Y, Duller P, et al. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol 2005;152:1275-81